|Systematic (IUPAC) name|
carboxylic acid methyl ester
|Bioavailability||7-86% (mean 33%)|
|Biological half-life||0.25-2.5 hours|
|Excretion||Urine (as metabolites)|
|CAS Registry Number|
|ATC code||G04 QV03|
354.44 g/mol (base)
390.90 g/mol (hydrochloride)
Yohimbine () is an indole alkaloid derived from the bark of the Pausinystalia yohimbe tree in Central Africa. It is a veterinary drug used to reverse sedation in dogs and deer. Yohimbine has been studied as a potential treatment for erectile dysfunction but there is insufficient evidence to rate its effectiveness. Extracts from yohimbe containing yohimbine have been used in traditional medicine in West Africa as an aphrodisiac and have been marketed as dietary supplements
- Uses 1
- Toxicity 2
- Extracts and chemistry 3
- Pharmacology 4
- Sexual dysfunction 5.1
- See also 6
- References 7
Yohimbine is a drug used in veterinary medicine to reverse the effects of xylazine in dogs and deer.
Yohimbe extracts, which contain yohimbine, have been used in traditional medicine in West Africa as an aphrodisiac and yohimbe extracts have been marketed as dietary supplements.
Depending on dosage, yohimbine can either increase or decrease systemic blood pressure (through vasoconstriction or vasodilation, respectively); small amounts of yohimbine can increase blood pressure, while large amounts can dangerously lower blood pressure. Higher doses of oral yohimbine may create numerous side effects, such as rapid heart rate, overstimulation, anomalous blood pressure, cold sweating, and insomnia.
Extracts and chemistry
Yohimbe (Pausinystalia johimbe) is a tree that grows in western and central Africa; yohimbine was originally extracted from the bark of yohimbe in 1896 by Adolph Spiegel. In 1943 the correct constitution of yohimbine was proposed by Witkop. Fifteen years later, Van Tamelen used a 23-step synthesis to become the first person to achieve the synthesis of yohimbine.
Yohimbine has high affinity for the α2-adrenergic receptor, moderate affinity for the α1 receptor, 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2B, and D2 receptors, and weak affinity for the 5-HT1E, 5-HT2A, 5-HT5A, 5-HT7, and D3 receptors. It behaves as an antagonist at α1-adrenergic, α2-adrenergic, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, and D2, and as a partial agonist at 5-HT1A. Yohimbine interacts with serotonin and dopamine receptors in high concentrations.
(Ki in nanomoles)
Yohimbine has been studied as a potential treatment for erectile dysfunction but there is insufficient evidence to rate its effectiveness. It is illegal in the United States to market an over the counter product containing yohimbine as a treatment for erectile dysfunction without getting FDA approval to do so.
Yohimbine blocks the pre- and post-synaptic α2 receptors. Blockade of post-synaptic α2 receptors causes minor corpus cavernosum smooth muscle relaxation. In fact, the majority of adrenoceptors in the corpus cavernosum are of the α1 type. Blockade of pre-synaptic α2 receptors facilitates the release of several neurotransmitters in the central and peripheral nervous system — thus in the corpus cavernosum — such as nitric oxide and norepinephrine. Whereas nitric oxide released in the corpus cavernosum is the major vasodilator contributing to the erectile process, norepinephrine is the major vasoconstrictor through stimulation of α1 receptors on the corpus cavernosum smooth muscle. Under physiologic conditions, nitric oxide attenuates norepinephrine vasoconstriction.
- Hedner, T; Edgar, B; Edvinsson, L; Hedner, J; Persson, B; Pettersson, A (1992). "Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers". European Journal of Clinical Pharmacology 43 (6): 651–656.
- yohimbine. (n.d.) Collins English Dictionary – Complete and Unabridged. (1991, 1994, 1998, 2000, 2003). Retrieved January 27, 2015 from http://www.thefreedictionary.com/yohimbine
- "Yohimbe: MedlinePlus Supplements". Medline. Retrieved 2013-05-26.
- Andersson KE (September 2001). "Pharmacology of penile erection". Pharmacological Reviews 53 (3): 417–50.
- Beille, P. E. (2013). "Scientific Opinion on the evaluation of the safety in use of Yohimbe (Pausinystalia yohimbe)".
- 21 CFR Sec. 522.2670 Yohimbine
- Kew World Checklist of Selected Plant Families, Pausinystalia johimbe
- Year Book of the American Pharmaceutical Association. American Pharmaceutical Association. 1914. p. 564. Retrieved 2015-05-04.
- Witkop, B. (1943),
- The Alkaloids: Chemistry and Pharmacology. Academic Press. 1988. p. 564.
- van Tamelen, E. E. (1958). "The Total Synthesis of Yohimbine".
- Herle, B. (2011). "Total Synthesis of (+)-Yohimbine via an Enantioselective Organocatalytic Pictet–Spengler Reaction".
- Millan MJ, Newman-Tancredi A, Audinot V, et al. (February 2000). "Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states". Synapse 35 (2): 79–95.
- "PDSP Ki Database".
- Arthur JM, Casañas SJ, Raymond JR (June 1993). "Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors".
- Kaumann AJ (June 1983). "Yohimbine and rauwolscine inhibit 5-hydroxytryptamine-induced contraction of large coronary arteries of calf through blockade of 5 HT2 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology 323 (2): 149–54.
- Baxter GS, Murphy OE, Blackburn TP (May 1994). "Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle".
- "Yohimbine (PIM 567)". Inchem.org. Retrieved 2013-05-26.
- National Institute of Mental Health. "PDSP Ki Database". University of North Carolina. Retrieved 5 July 2013.
- "Yohimbine". DrugBank. University of Alberta. Retrieved 12 April 2014.
- FDA regulations on OTC products
- Saenz De Tejada, I; Kim, NN; Goldstein, I; Traish, AM (2000). "Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum". International Journal of Impotence Research. 12 Suppl 1: S20–25.